'Co-clinical trials' have been proposed as way to evaluate new therapies. In this approach, drugs are tested simultaneously in clinical and preclinical trials. To demonstrate its potential, Zhao Chen et al. used genetically engineered mouse models alongside a randomized phase II trial of the chemotherapeutic drug docetaxel, used both alone and in combination with a MEK inhibitor in KRAS-driven lung cancer.
展开▼
